½ÃÀ庸°í¼­
»óǰÄÚµå
1597805

¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå : ¿ë·®, Åõ¿© °æ·Î, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Sustained Release Injectables Market by Dosage (In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems), Route of Administration (Interarterial, Intracardiac, Intradermal), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 21¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 22¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.95%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 34¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼­¹æÇü ÁÖ»çÁ¦´Â Á¦¾à »ê¾÷¿¡¼­ ¸Å¿ì Áß¿äÇÑ ºÐ¾ß·Î, Àå±â°£¿¡ °ÉÃÄ ¾à¹°À» Á¡ÁøÀûÀ¸·Î ¹æÃâÇÏ¿© ȯÀÚÀÇ ¼øÀÀµµ¿Í Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â Á¦Á¦¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ»çÁ¦´Â ¸¸¼º Áúȯ Ä¡·á¿¡ ¸Å¿ì Áß¿äÇϸç, ¾ÈÁ¤ÀûÀÎ ¾à¹° ¹æÃâÀ» ÅëÇØ Åõ¿© ºóµµ¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â Á¾¾çÇÐ, ³»ºÐºñÇÐ, ½Å°æÇÐ µî Ä¡·á ºÐ¾ß¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀü, °£ÆíÇÑ Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ È°¼ºÈ­µÇ°í ÀÖ½À´Ï´Ù. °ü¸®Çϱ⠽¬¿î Àå±â Åõ¾à ¼Ö·ç¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â ³ëÀÎ Àα¸°¡ ±ÞÁõÇϰí ÀÖ´Â °Íµµ Å« ±âȸÀÔ´Ï´Ù. ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¾ÈÀü¼º°ú È¿À²¼ºÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ´Â ¾à¹° ĸ½¶È­¿ë »ýºÐÇØ¼º Æú¸®¸Ó¸¦ °³¹ßÇϱâ À§ÇÑ Çõ½ÅÀûÀÎ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÅÈï±¹ ½ÃÀåÀº ³ôÀº °³¹ß ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç µîÀÇ Á¦¾à¿¡ Á÷¸éÇØ ÀÖ¾î ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÎÀÛ¿ëÀÇ °¡´É¼º, Á¦ÇüÀÇ º¹À⼺ µîµµ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµÀü¿¡µµ ºÒ±¸Çϰí, ½ÃÀå¿¡´Â ±âȸ°¡ ³ÑÃijª°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¹æÃâ Á¦¾î ¸ÞÄ¿´ÏÁò¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â »õ·Î¿î »ýºÐÇØ¼º ¼ÒÀç¿Í ³ª³ë±â¼úÀÇ ÅëÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. Çмú ±â°ü°úÀÇ Çù·ÂÀº ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇϸ鼭 Çõ½ÅÀ» ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº Á¡Á¡ ´õ Ä¡¿­ÇØÁö°í ÀÖÀ¸¸ç, ±â¼ú ¹ßÀü°ú ½ÃÀå ħÅõ¸¦ À§ÇÑ Àü·«Àû Á¦ÈÞ¿Í ÇÕº´ÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â Á¤±³ÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í R&D¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ¿©ÀüÈ÷ ¾ÐµµÀûÀÎ °­¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÈï ½ÃÀåÀº ÀÇ·á ½Ã½ºÅÛ °³¼±°ú ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¹Ì°³Ã´ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. °á·ÐÀûÀ¸·Î, ¼­¹æÇü ÁÖ»çÁ¦´Â ¼ºÀå ÀáÀç·ÂÀÌ Å« ¿ªµ¿ÀûÀÎ ½ÃÀåÀ̸ç, ¼º°øÀûÀÎ »ç¾÷ È®ÀåÀ» À§Çؼ­´Â Àü·«Àû Çõ½Å°ú ±ÔÁ¦ ȯ°æ¿¡ ´ëÇÑ ÁøÁöÇÑ Å½»öÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 21¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 22¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 34¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 6.95%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ýȰ½À°ü ¾ÇÈ­·Î ÀÎÇÑ ÁÖ¿ä ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
    • ¼Ò¾Æ ¹× ³ë³âÃþ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ ¼­¹æÇü ÁÖ»çÁ¦ ¼ö¿ä Áõ°¡
    • ÁÖ»çÁ¦´Â °æ±¸Á¦º¸´Ù »ýü ÀÌ¿ë·üÀÌ ³ô½À´Ï´Ù.
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÃæÁø ½Ã À¯º¯ÇÐÀûÀÎ º¯È­, Àå±â º¸°ü ½Ã ºÒ¾ÈÁ¤¼º, ¹æÃâ ¼ÓµµÀÇ ºñÁ¶Á¤¼º
  • ½ÃÀå ±âȸ
    • ³ª³ë±â¼ú, ¹Ì¼¼È­, ¾ÈÁ¤È­ °øÁ¤ µîÀÇ ±â¼ú ¹ßÀü
    • õ¿¬ ¹× È­ÇÐÇÕ¼º »ýºÐÇØ¼º Àç·á ¼Ò°³
  • ½ÃÀå °úÁ¦
    • ¾àÁ¦ºñ Æøµî°ú ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·

Portre's Five Forces: ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå : Åõ¿©·®º°

  • In Situ Forming Formulations
  • In Situ Forming Gel System
  • In Situ Forming Microparticle Systems
  • Liposome
  • Microcapsule
  • Microsphere
  • Polymeric Micelles

Á¦7Àå ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°

  • µ¿¸Æ°£
  • ½ÉÀå³»
  • Çdz»
  • ±ÙÀ°³»
  • Á¤¸Æ³»
  • ÇÇÇÏ

Á¦8Àå ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Áø´Ü ½ÇÇè½Ç
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼­¹æÇü ÁÖ»çÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Dr. Reddy's Laboratories
  • GP Pharm S.A.
  • Innocore Pharmaceuticals
  • Janssen Pharmaceutical Companies by Johnson & Johnson
  • Novartis AG
  • Oakwood Laboratories
  • Pacira Pharmaceuticals, Inc.
  • PhaseBio Pharmaceuticals, Inc
  • Taiwan Liposome Company(TLC)
  • ViiV Healthcare
  • Xbrane Biopharma AB
LSH

The Sustained Release Injectables Market was valued at USD 2.15 billion in 2023, expected to reach USD 2.29 billion in 2024, and is projected to grow at a CAGR of 6.95%, to USD 3.45 billion by 2030.

Sustained Release Injectables are a pivotal segment within the pharmaceutical industry, focusing on formulations that allow for the gradual release of medication over an extended period, thereby improving patient compliance and therapeutic outcomes. These injectables are crucial in treating chronic conditions, offering a steady drug release that reduces the frequency of administration and enhances patient adherence. Key applications span across therapeutic areas such as oncology, endocrinology, and neurology. The market is fueled by the rising prevalence of chronic diseases, advancements in drug delivery technologies, and a growing preference for convenient treatment regimens. A significant opportunity lies in the burgeoning geriatric population who require manageable long-term medication solutions. Innovative research is directed towards developing biodegradable polymers for drug encapsulation, which can significantly enhance the safety and efficiency of drug delivery systems. However, the market faces limitations such as the high cost of development and stringent regulatory requirements, which can impede growth. Additionally, potential adverse reactions and the complexity of formulation pose challenges. Despite these challenges, the market is rife with opportunities. Companies are recommended to invest in research focused on novel biodegradable materials and Nanotechnology integration, which could revolutionize controlled release mechanisms. Collaborations with academic institutions could prove fruitful in driving innovation while ensuring compliance with regulatory standards. The market is increasingly competitive, fostering a surge in strategic alliances and mergers to leverage technological advancements and market penetration. North America remains a dominant player due to its sophisticated healthcare infrastructure and substantial investment in R&D. However, emerging markets in Asia-Pacific present untapped potential given their improving healthcare systems and growing demand for advanced therapeutics. In conclusion, sustained release injectables embody a dynamic market with significant growth potential, demanding strategic innovation and diligent navigation of regulatory landscapes for successful business expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.15 billion
Estimated Year [2024] USD 2.29 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 6.95%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sustained Release Injectables Market

The Sustained Release Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
    • Rise in demand for paediatric and geriatric sustained release injectables
    • Injectable preparations have a better bioavailability than oral preparations
  • Market Restraints
    • Rheological changes during filling, instability on long-term storage and nonadjustable release rate
  • Market Opportunities
    • Advancement in technology such as nanotechnology, micronation, and stabilization process
    • Introduction of natural and chemosynthetic biodegradable materials
  • Market Challenges
    • High cost of drugs and lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Sustained Release Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sustained Release Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sustained Release Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sustained Release Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sustained Release Injectables Market

A detailed market share analysis in the Sustained Release Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sustained Release Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sustained Release Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sustained Release Injectables Market

A strategic analysis of the Sustained Release Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sustained Release Injectables Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories, GP Pharm S.A., Innocore Pharmaceuticals, Janssen Pharmaceutical Companies by Johnson & Johnson, Novartis AG, Oakwood Laboratories, Pacira Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc, Taiwan Liposome Company (TLC), ViiV Healthcare, and Xbrane Biopharma AB.

Market Segmentation & Coverage

This research report categorizes the Sustained Release Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage, market is studied across In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems, Liposome, Microcapsule, Microsphere, and Polymeric Micelles.
  • Based on Route of Administration, market is studied across Interarterial, Intracardiac, Intradermal, Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
      • 5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
      • 5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
    • 5.1.2. Restraints
      • 5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
      • 5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of drugs and lack of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sustained Release Injectables Market, by Dosage

  • 6.1. Introduction
  • 6.2. In Situ Forming Formulations
  • 6.3. In Situ Forming Gel System
  • 6.4. In Situ Forming Microparticle Systems
  • 6.5. Liposome
  • 6.6. Microcapsule
  • 6.7. Microsphere
  • 6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Interarterial
  • 7.3. Intracardiac
  • 7.4. Intradermal
  • 7.5. Intramuscular
  • 7.6. Intravenous
  • 7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Dr. Reddy's Laboratories
  • 2. GP Pharm S.A.
  • 3. Innocore Pharmaceuticals
  • 4. Janssen Pharmaceutical Companies by Johnson & Johnson
  • 5. Novartis AG
  • 6. Oakwood Laboratories
  • 7. Pacira Pharmaceuticals, Inc.
  • 8. PhaseBio Pharmaceuticals, Inc
  • 9. Taiwan Liposome Company (TLC)
  • 10. ViiV Healthcare
  • 11. Xbrane Biopharma AB
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦